Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02297126 · ClinicalTrials.gov registry record · NA
A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 4,465
- Enrollment target
NCT02297126: Completed NA study, sponsored by Indiana University.
NCT02297126 is a NA study that has completed, run by Indiana University. The registered enrollment target is 4,465 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (218% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02297126, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 4,465 participants
- Enrollment target
Study Summary
The INGenious trial will prospectively enroll a total of 6,000 patients, with 2,000 patients assigned to a pharmacogenetic testing arm and 4,000 to a control arm who will be followed, but not tested. It is randomized between an intervention arm and one that receives no intervention in order that the genotyped group can be compared with one in which undisturbed, routine clinical care is carried out in patients taking the same drugs. Both arms will be followed for a year after being prescribed a targeted medication. Patients randomized into the intervention arm that are prescribed one or more of the 24 targeted index medication will receive pharmacogenomic testing using a custom micro-array measuring 51 Single nucleotide polymorphisms in 16 genes. The study is being conducted by the Indiana University School of Medicine and the Indiana University Institute of Personalized Medicine in collaboration with the Eskenazi and Indiana University Health Systems and will evaluate the economic and clinical outcomes associated with embedding a pharmacogenomics program in a system that serves as the primary health care safety-net in Indianapolis, Indiana. By successfully implementing a pharmacogenomics program and integrating it with the Electronic Health Record and Clinical Decision Support system, physicians will be able to optimize patient care by delivering tailored therapeutic decisions based on the patient's individual genetics.
Primary Outcome
Analysis of cost of care (measured in U.S. dollars) data from the Eskenazi and Indiana University Health electronic medical records and billing systems for patients in the study. Charge data collected from monthly Eskenazi and IU Health System reports generated for the state hospital association. Categories of inpatient and outpatient charges include costs for medications, facility, laboratory, treatment, professional, and other sources. Data will be collected for each patient in the control and
Interventions
- OTHER Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,465 participants |
| Start Date | 2015-03 |
| Est. Completion | 2019-05-03 |
| Phase | NA |
What the finished NCT02297126 record still lists
NCT02297126 is an interventional study that assigns participants to a tested intervention. Its 4,465 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (218% higher).
The record links to 0 conditions, and to 1 intervention - of which Pharmacogenetic Intervention Arm (pharmacogenetic testing) is the first listed.
NCT02297126 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02297126 about?
NCT02297126 is a clinical study titled "A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program". The INGenious trial will prospectively enroll a total of 6,000 patients, with 2,000 patients assigned to a pharmacogenetic testing arm and 4,000 to a control arm who will be followed, but not tested. It is randomized between an intervention arm and one that receives no intervention in order that the...
What is the current status of trial NCT02297126?
This trial is currently completed. It is a NA study. The enrollment target is 4,465 participants. The study started on 2015-03. Estimated completion is 2019-05-03.
What interventions are being tested in trial NCT02297126?
The interventions under investigation include: Pharmacogenetic Intervention Arm (pharmacogenetic testing) (OTHER).
Who is sponsoring clinical trial NCT02297126?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02297126's enrollment target sits among peer trials
4,465 30th of 2000 higher than 1,971 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06252753 · 4,490 participants
Observational Study Protocol: LIVER-R
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
- NCT06588452 · 4,500 participants
Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models
- NCT07165028 · 4,500 participants · Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia